(Health-NewsWire.Net, May 19, 2016 ) Publisher's, 'Leber Congenital Amaurosis (LCA) - Pipeline Review, H1 2016', provides an overview of the Leber Congenital Amaurosis (LCA) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leber Congenital Amaurosis (LCA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leber Congenital Amaurosis (LCA) and features dormant and discontinued projects. Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Other Key Points in Report:
- The report provides a snapshot of the global therapeutic landscape of Leber Congenital Amaurosis (LCA) - The report reviews pipeline therapeutics for Leber Congenital Amaurosis (LCA) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Leber Congenital Amaurosis (LCA) therapeutics and enlists all their major and minor projects - The report assesses Leber Congenital Amaurosis (LCA) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
Inquire before Purchasing Report @ http://www.reportsweb.com/inquiry&RW0001239357/buying
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Leber Congenital Amaurosis (LCA) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Leber Congenital Amaurosis (LCA) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Ask for Sample Report @ http://www.reportsweb.com/inquiry&RW0001239357/sample
Table of Content: An Overview
Introduction 5 Publisher Report Coverage 5 Leber Congenital Amaurosis (LCA) Overview 6 Therapeutics Development 7 Pipeline Products for Leber Congenital Amaurosis (LCA) - Overview 7 Pipeline Products for Leber Congenital Amaurosis (LCA) - Comparative Analysis 8 Leber Congenital Amaurosis (LCA) - Therapeutics under Development by Companies 9 Leber Congenital Amaurosis (LCA) - Therapeutics under Investigation by Universities/Institutes 10 Leber Congenital Amaurosis (LCA) - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Leber Congenital Amaurosis (LCA) - Products under Development by Companies 14 Leber Congenital Amaurosis (LCA) - Products under Investigation by Universities/Institutes 15 Leber Congenital Amaurosis (LCA) - Companies Involved in Therapeutics Development 16 AmpliPhi Biosciences Corporation 16 Editas Medicine, Inc. 17 ProQR Therapeutics N.V. 18 QLT Inc. 19 Spark Therapeutics, Inc. 20 Leber Congenital Amaurosis (LCA) - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001239357/discount
Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 Gene Therapy for Leber Congenital Amaurosis - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Gene Therapy to Activate Retinal Guanylyl Cyclase-1 for Leber Congenital Amaurosis-1 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Gene Therapy to Activate RPE65 for Leber Congenital Amaurosis - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 QR-110 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 tgAAG-76 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 voretigene neparvovec - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 zuretinol acetate - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001239357/buy/2000
About Us:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us: Email: sales@reportsweb.com Call: +1-646-491-9876
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|